CGT

117개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved117 programs
CGTLimited DatastaleMedical College of WisconsinPhase 2

8/12-Day Production of Cryopreserved Car-T Cells (8/12-Day Production of Cryopreserved Car-T Cells)

Non Hodgkin Lymphoma (NHL); Mantle Cell Lymphoma (MCL) · Non Hodgkin Lymphoma (NHL)

#NonHodgkinLymphomaNHL#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 2

AMT-116 CAR-T cells (AMT-116 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 2

AMT-253 CAR-T cells (AMT-253 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBaylor College of MedicinePhase 1

Allogeneic CD5.CAR/28zeta CAR T cells (Allogeneic CD5.CAR/28zeta CAR T cells)

T-cell Acute Lymphoblastic Lymphoma; T-non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Lymphoma

#T-cellAcuteLymphoblasticLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleHenan Cancer HospitalPhase 2

Anti-Trop2 CAR-NK cell (Anti-Trop2 CAR-NK cell)

Non-Small Cell Lung Cancer NSCLC · TROP2

#TROP2#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleRochePhase 1

atezolizumab (Tecentriq, Atezolizumab and Interleukin-12 Gene Therapy)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleMayo ClinicPhase 1

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 (Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563)

Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMayo ClinicPhase 1

Autologous BAFFR-targeting CAR T Cells (Autologous BAFFR-targeting CAR T Cells)

B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD38 dual-target CAR-T module (Autologous BCMA/CD38 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD22 dual-target CAR-T module (Autologous CD19/CD22 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CD123 dual-target CAR-T module (Autologous CD33/CD123 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CLL1 dual-target CAR-T module (Autologous CD33/CLL1 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

Autologous CD5.CAR/28zeta CAR T cells (Autologous CD5.CAR/28zeta CAR T cells)

T-cell Acute Lymphoblastic Lymphoma; T-non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Lymphoma

#T-cellAcuteLymphoblasticLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD5/CD7 dual-target CAR-T module (Autologous CD5/CD7 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 1

CAR T cells chimeric antigenreceptor cells (CAR T cells chimeric antigenreceptor cells)

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma; Relapsed/Refractory B-cell ALL · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

CAR-NK (CAR-NK)

Pancreatic Cancer Non-resectable · Pancreatic Cancer Non-resectable

#PancreaticCancerNon-resectable#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleHebei Taihe Chunyu Biotechnolog…Phase 2

CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） (CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）)

Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL); AML (Acute Myelogenous Leukemia) · Lymphoma, B-cell, Aggressive Non-Hodgkin

#LymphomaB-cellAggressiveNon-Hodg#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting

3 / 6 pages

← PreviousNext →